Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onalespib in Relapsed/Refractory ALK+ ALCL, MCL, and BCL6+ DLBCL
NCT02572453Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of onalespib in anaplastic large cell lymphoma (ALCL), mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate. Started Apr 2016; status: terminated.
02
Drugs
onalespib
03
Conditions
anaplastic large cell lymphoma (ALCL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02572453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02572453.